Newly discovered process for p53 gene regulation sheds light on how to make cancer therapies more effective
Scientists at VCU Massey Cancer Center have discovered that the loss of a protein called DBC1 in breast cancer cells leads to the dysregulation of normal anti-cancer functions, contributing to cancer cell growth and resistance to therapies. By restoring the expression of this protein, doctors may be able to help prevent the development of cancer and increase the effectiveness of common cancer treatments.
Recently published in the journal Cell Reports, the study used mass spectrometry to identify proteins that interact with processes that regulate the gene p53, which normally acts to suppress the development of cancer and has been found to be dysregulated in a majority of cancer types.
“We screened for proteins that interact with a protein within the nucleus of cells called CREB binding protein (CBP) that is known to regulate the gene p53. We found one of the proteins discovered in this screen called DBC1 is critical to maintaining the levels and activity of p53, and the gene encoding for this protein is frequently deleted in breast cancer cells,” says the study’s lead author Steven R. Grossman, M.D., Ph.D., deputy director of VCU Massey Cancer Center, Dianne Nunnally Hoppes Endowed Chair in Cancer Research and member of Massey’s Cancer Molecular Genetics and Developmental Therapeutics research programs.
Previous research has shown that the CBP works with another protein known as MDM2 to maintain p53 levels in cells. This latest work from Dr. Grossman’s laboratory shows that DBC1 regulates CBP activity, and therefore plays an essential role in maintaining p53 activity and abundance in normal cells.
“Restoring the function of DBC1 could potentially make tumors more susceptible to current cancer treatments and help prevent further cancer growth,” says Grossman, who is also the chair of the Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine.
The scientists used human breast cancer cell lines and mouse models to test their findings. They discovered that DBC1 levels decrease in response to cellular stress, which can be caused by platinum-based cancer drugs, for example. This drop in DBC1 decreased p53 levels, making the cells resistant to p53-mediated apoptosis, a form of controlled cell suicide. Many cancer drugs work by inducing apoptotic cell death.
Grossman and his team showed that maintaining DBC1 levels in cancer cells exposed to cisplatin, a platinum-based cancer drug, caused a substantially increased response to the drug.
“This shows that cancer cells have developed finely tuned responses to control DBC1 levels in order to avoid exaggerated apoptotic responses,” says Grossman. “We’re hopeful we can intervene in these processes and develop new strategies that increase the effectiveness of therapies for a variety of cancers shown to have dysregulated DBC1 levels, such as breast, lung and prostate cancers.”
Grossman collaborated on this research with Lisa Litovchick, M.D., Ph.D., member of the Cancer Molecular Genetics research program at Massey and associate professor in the Department of Internal Medicine at the VCU School of Medicine; Barbara Szomju and Priyadarshan Damle, Ph.D., both from the Department of Internal Medicine at the VCU School of Medicine; Oluwatoyin Akande, Ph.D., postdoctoral fellow in the Department of Internal Medicine at the VCU School of Medicine; Marius Pop, Ph.D., from Kronos Bio, Inc.; and Nicholas Sherman, Ph.D., from the University of Virginia.
This research was supported by National Cancer Institute grant R01 CA107532 and, in part, by Massey Cancer Center’s NIH/NCI Cancer Center Support Grant P30 CA016059.